Loading clinical trials...

Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02) | Clinical Trials | Clareo Health

RECRUITINGPHASE1/PHASE2

Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)

A Phase 1/2 Study to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Gastrointestinal Cancers

NCT06596694•Merck Sharp & Dohme LLC

View on ClinicalTrials.gov

Summary

Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are advanced (the cancer has spread to other parts of the body). The goals of this study are to learn: * About the safety and how well people tolerate of patritumab deruxtecan * How many people have the cancer respond (get smaller or go away) to treatment

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Has one of the following cancers:
•* Unresectable or metastatic colorectal cancer.
•* Advanced and/or unresectable biliary tract cancer (BTC)
•* Hepatocellular carcinoma (HCC) not amenable to locoregional therapy
•* Locally advanced unresectable or metastatic gastroesophageal cancer
•Has received prior therapy for the cancer.
•Has recovered from any side effects due to previous cancer treatment

Exclusion Criteria

•Has a history of (noninfectious) interstitial lung disease (ILD) or pneumonitis that required steroids, or has current ILD or pneumonitis, and/or suspected ILD or pneumonitis that cannot be ruled out by standard diagnostic assessments at Screening
•Has clinically severe respiratory compromise (based on the investigator's assessment) resulting from intercurrent pulmonary illnesses
•Has evidence of any leptomeningeal disease
•Has clinically significant corneal disease
•Has uncontrolled, significant cardiovascular disease or cerebrovascular disease
•Has evidence of ongoing uncontrolled systemic bacterial, fungal, or viral infection

Locations (62)

UCLA Hematology Oncology Santa Monica ( Site 1205)

Santa Monica, California, United States

University of Colorado Cancer Center ( Site 1200)

Aurora, Colorado, United States

Sibley Memorial Hospital ( Site 1208)

Washington D.C., District of Columbia, United States

University of Florida ( Site 1202)

Gainesville, Florida, United States

Mount Sinai Medical Center Comprehensive Cancer Center ( Site 1213)

Miami Beach, Florida, United States

Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 1203)

Marietta, Georgia, United States

University of Chicago Medical Center ( Site 1204)

Chicago, Illinois, United States

Renown Regional Medical Center ( Site 1221)

Reno, Nevada, United States

NYU Langone Hospital - Long Island ( Site 1230)

Mineola, New York, United States

Perlmutter NYU Cancer Center ( Site 1212)

New York, New York, United States

Key Dates

Start Date

November 3, 2024

Primary Completion Date

December 7, 2028

Completion Date

December 7, 2028

Last Updated

March 16, 2026

Enrollment

180

ESTIMATED participants

Conditions

Gastrointestinal Cancer

Interventions

Patritumab deruxtecan

BIOLOGICAL

Contacts

Toll Free Number

CONTACT

1-888-577-8839 Trialsites@msd.com

Resilience and Equity in Aging, Cancer, and Health (REACH)

NCT04674267

Gastric CancerColon Cancer+4 more

View study

RECRUITINGPHASE1/PHASE2

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

NCT06445062

Colorectal CancerCRC+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 16, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)

Inclusion Criteria

Exclusion Criteria

Resilience and Equity in Aging, Cancer, and Health (REACH)

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Acquisition of Blood and Tumor Tissue Samples From Patients With Gastrointestinal Cancer

PhI Pilot Study Pafolacianine Inject for Intraoperative Imaging on Outcomes of GI Cancer Peritoneal Carcinomatosis

A Study on the Effects of Exercise on Side Effects From Treatment for Gastrointestinal Cancers

Immunobiology Blood and Tissue Collection of Upper Aerodigestive Malignancies